Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
NCT ID: NCT00133874
Last Updated: 2017-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
520 participants
INTERVENTIONAL
2005-04-30
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
NCT01670032
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
NCT01367314
The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
NCT01943136
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
NCT03017846
Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies
NCT05862701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB-275833 ointment, 1%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.
Exclusion Criteria
* Any serious underlying disease that could be imminently life threatening.
9 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Kitchener, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
San José, , Costa Rica
GSK Investigational Site
Anzin, , France
GSK Investigational Site
Bersée, , France
GSK Investigational Site
Labarth-Sur-Leze, , France
GSK Investigational Site
Martigues, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Seraincourt, , France
GSK Investigational Site
Vieux-Condé, , France
GSK Investigational Site
Augsburg, Bavaria, Germany
GSK Investigational Site
Gilching, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Mahlow, Brandenburg, Germany
GSK Investigational Site
Duelmen, Lower Saxony, Germany
GSK Investigational Site
Bad Honnef, North Rhine-Westphalia, Germany
GSK Investigational Site
Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Düsseldorf, North Rhine-Westphalia, Germany
GSK Investigational Site
Gelsenkirchen, North Rhine-Westphalia, Germany
GSK Investigational Site
Kleve-Materborn, North Rhine-Westphalia, Germany
GSK Investigational Site
Krefeld, North Rhine-Westphalia, Germany
GSK Investigational Site
Mülheim, North Rhine-Westphalia, Germany
GSK Investigational Site
Olpe, North Rhine-Westphalia, Germany
GSK Investigational Site
Unna, North Rhine-Westphalia, Germany
GSK Investigational Site
Wuppertal, North Rhine-Westphalia, Germany
GSK Investigational Site
Worms, Rhineland-Palatinate, Germany
GSK Investigational Site
Döbeln, Saxony, Germany
GSK Investigational Site
Dresden, Saxony, Germany
GSK Investigational Site
Reichenbach, Saxony, Germany
GSK Investigational Site
Schmiedeberg, Saxony, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany
GSK Investigational Site
Preetz, Schleswig-Holstein, Germany
GSK Investigational Site
Rendsburg, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Mumbai, , India
GSK Investigational Site
Zapopan, Jalisco, Jalisco, Mexico
GSK Investigational Site
Mexico City, , Mexico
GSK Investigational Site
Ermelo, , Netherlands
GSK Investigational Site
Huizen, , Netherlands
GSK Investigational Site
Losser, , Netherlands
GSK Investigational Site
Musselkanaal, , Netherlands
GSK Investigational Site
Oude Pekela, , Netherlands
GSK Investigational Site
Sittard, , Netherlands
GSK Investigational Site
Soerendonk, , Netherlands
GSK Investigational Site
Zieuwent, , Netherlands
GSK Investigational Site
Zwijndrecht, , Netherlands
GSK Investigational Site
Breña, , Peru
GSK Investigational Site
Grudziądz, , Poland
GSK Investigational Site
Katowice, , Poland
GSK Investigational Site
Poznan, , Poland
GSK Investigational Site
Wroclaw, , Poland
GSK Investigational Site
Zabrze, , Poland
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Cape Town, , South Africa
GSK Investigational Site
Daveyton, , South Africa
GSK Investigational Site
Eloffsdal, Pretoria, , South Africa
GSK Investigational Site
Newtown, , South Africa
GSK Investigational Site
Pretoia, , South Africa
GSK Investigational Site
Pretoria, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOC100224
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.